Contact Us

Bio-Etc Pte Ltd
60, Paya Lebar Road,
#11-06 Paya Lebar Square,
Singapore 409051

 

Tel: +65 9025 9897
Email: info@bio-etc.com

Social Media

[MCE] New products for September 2023

[MCE] New products for September 2023

MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel bioactive compounds, dye reagents, peptides and natural compounds for laboratory and scientific use.

•  Over 50,000 bioactive molecules in stock
•  Target 1,000+ key proteins in 20+ signaling pathways
•  Quality reports (LC/MS, NMR and HPLC) for each product
•  Release more than 1,000 latest biochemicals per month
•  Data sheet with detailed biological information
•  High purity & competitive prices
•  Delivery within 24 hours

CAS No.: 2937327-93-8

BI-2865

Research Area: Ras/KRAS/Cancer

BI-2865 structure
A non-covalent pan-KRAS inhibitor that binds to wild-type, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM, respectively.
Potently inhibits the proliferation of isogenic G12C, G12D or G12V mutant KRAS expressing BaF3 cells, with a mean IC50 of ~140 nM.

Solubility: DMSO : 250 mg/mL (536.98 mM; Need ultrasonic)

CAS No.: 2089314-64-5

AOH1996

Research Area: DNA/RNA Synthesis/PCNA/Solid Tumors

AOH1996 structure
An orally active proliferating cell nuclear antigen (PCNA) inhibitor, which selectively kills cancer cells.
Enhances the interaction of PCNA and the largest subunit of RNA polymerase II, rpb1, causing proteasome-dependent degradation of rpb1 and lethal DNA damages.

Solubility: DMSO : 125 mg/mL (293.11 mM; Need ultrasonic)

CAS No.: 2924573-90-8

FX-909

Research Area: PPAR/PPARG/Urothelial Cancer

FX-909 structure
A highly selective, orally active and covalent PPAR-gamma (PPARG) inverse agonist, showing >2000-fold selectivity for PPARG over PPARA/PPARD.
Inhibits cell growth in urothelial cancer (UC) cell lines with activated PPARG signaling but has no effect on cell lines without activated PPARG.
Used for the research in advanced urothelial cancer (UC).

Solubility: DMSO : 100 mg/mL (277.52 mM; Need ultrasonic)

CAS No.: 1507370-40-2

BC-1258

Research Area: E1/E2/E3 Enzyme/FBXL2/Cancer

BC-1258 structure
A potent F-box/LRR-repeat protein 2 (FBXL2) activator that stabilizes and increases levels of FBXL2 protein.
Promotes Aurora B degradation, induces tetraploidy, mitotic arrest and apoptosis of tumorigenic cells.
A FBXO3 inhibitor, with a broad range of antitumor activity.

Solubility: DMSO : 125 mg/mL (307.45 mM; Need ultrasonic)

MCE New Compound Library in August
HY-L156 Autoimmune Disease Compound Library
Autoimmune disease is a pathological disease characterized by imbalance of inflammatory cytokines. The current targeted immunotherapy suppresses
the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF, IL-1 β, IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL). MCE designs a unique collection of 400+ autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.
HY-L161 Cytokine Inhibitors Library
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by cells which induced by immunogen, mitogen or other factors. Cytokines have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The imbalance of inflammatory cytokines is one of the important reasons for the occurrence of autoimmune diseases. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. MCE designs a unique collection of 900+ cytokine inhibitors, mainly targeting the IL, CSF, IFN, TNF, GF, etc., which is an effective tool for development and research of anti-autoimmune diseases, anti-cancer and anti-chronic inflammatory diseases compounds.

 

Endogenous metabolites
Endogenous metabolites are compounds produced by the body during metabolism, excluding substances derived from the metabolism of exogenous foods or drugs. In addition to maintaining basic life activities, endogenous metabolites also have important pharmacological effects. 1) A target for disease treatment, for example, Cholesterol as a target for hypercholesterolemia treatment. 2) A biomarker to diagnose or detect specific diseases and their therapeutic effects, such as blood sugar levels for diabetes.
3) As an important source of new drug development, such as hormone drugs.
Structure Product Name Description

L-2-Hydroxyglutaric acid
A potential glutamate carboxypeptidase inhibitor. Inhibits histone demethylase and promotes histone methylation.

Zymosterol
A precursor of Cholesterol, found mainly in the plasma membrane.

Escitalopram
A selective serotonin reuptake inhibitor for antidepressant research.

D-Thyroxine
A thyroid hormone that inhibits the secretion of TSH and is used in the study of hypercholesterolemia.

p-Cresyl sulfate
A major uremic toxin derived from the metabolites of Tyrosine and Phenylalanine through liver.

 

MCE Glycoscience Tools Enzymes
    Glycosylation is the process of attaching sugars to proteins under the action of glycosyltransferases to form glycosidic bonds with amino acid residues on proteins, which is the most abundant and diverse form of post-translational modification of proteins that is common to all eukaryotic cells. Glycosylation regulates the function and activity of proteins and affects biological processes such as cell recognition, differentiation, signal transduction, and immune response, etc. MCE offers a wide variety of enzymes for the glycosciences, click here for an up-to-date list of MCE enzymes!
Product Name CAS Description

beta-1, 3-N-Acetylhexaminyltransferase (LgtA)
37277-64-8 Catalyzes the transfer of N-acetylglucosamine from UDP-GlcNAc to N-acetyllactosamine and lactose.

beta-1,4-Galactosyltransferase (LgtB)
9054-94-8 Catalyzes the reaction involving UDP-galactose and N-acetylglucosamine for the production of galactose beta-1,4-N-acetylglucosamine.

alpha-2,6-Sialyltransferase (Pd26ST)
9075-81-4 Is capable of sialylating both terminal and internal galactose and N-acetylgalactosamine, which producing terminal α2,6-sialosides.

alpha-2,3-Sialyltransferase (PmST1)
71124-51-1 A sialyltransferase that can be isolated from Pasteurella multocida.

alpha-1,3/4-Fucosyltransferase (α1,3/4FucT)
37277-69-3 Catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc.

 

MCE Isotope-labeled Compounds
Cat. No. Product Name Structure

HY-132334S
9-cis-Retinoic acid-d5

HY-B0673S1
Deupirfenidone-d3

HY-10163S1
Dabigatran-d3

HY-N0113S
Hordenine-d6

Latest Publications Citing Use of MCE Products
Covers of Recent Publications Nature.
2023 Aug;620(7973):426-433.
Cancer Cell.
2023 Jun 12;41(6):1170-1185.e12.
Signal Transduct Target Ther.
2023 Jul 17;8(1):273.
Immunity.
2023 Jun 13;56(6):1303-1319.e5.


Cell Signaling Pathway

 

Tags: